WST Stock Recent News

NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc.") (NYSE:WST) concerning possible violations of federal securities laws. On February 12, 2025, West reported positive 4Q 2024 financial results but announced full year 2025 guidance that was well below analysts' expectations.

EXTON, Pa. , Feb. 20, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025.

The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction.

The final trades of the day with the Fast Money traders.

West Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales of $749 million and adjusted earnings per share of $1.82, compared to $740 million and $1.73, respectively.

West Pharmaceutical Services, Inc. (NYSE:WST ) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Securities Patrick Donnelly - Citigroup Inc. Paul Knight - KeyBanc Capital Markets Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank David Windley - Jefferies Jacob Johnson - Stephens Inc. Operator Thank you for standing by and welcome to West Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

West Pharmaceutical Services Inc.'s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of injectable-pharmaceutical packaging and delivery systems offered guidance for 2025 that was well below expectations.